TRxADE HEALTH, Inc. (MEDS)
USD 7.59
(4.55%)
USD 7.59
(4.55%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 6.95 Million USD | 1443.95% |
| 2022 | 450.27 Thousand USD | 124.03% |
| 2021 | -1.87 Million USD | 64.59% |
| 2020 | -5.29 Million USD | -182.41% |
| 2019 | -1.87 Million USD | -7247.12% |
| 2018 | -25.5 Thousand USD | -105.29% |
| 2017 | 482.45 Thousand USD | -37.07% |
| 2016 | 766.67 Thousand USD | 209.69% |
| 2015 | 247.55 Thousand USD | 135.08% |
| 2014 | -705.6 Thousand USD | -985.81% |
| 2013 | -64.98 Thousand USD | -1823.74% |
| 2012 | -3378.00 USD | 0.0% |
| 2008 | 18.64 Million USD | 1052951.5% |
| 2007 | -1771.00 USD | 86.56% |
| 2006 | -13.17 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -7.52 Million USD | -128.26% |
| 2024 Q1 | -3.29 Million USD | -147.43% |
| 2023 FY | 6.95 Million USD | 1443.95% |
| 2023 Q2 | 242.43 Thousand USD | 253.89% |
| 2023 Q1 | -157.53 Thousand USD | -134.99% |
| 2023 Q4 | 6.95 Million USD | 7.8% |
| 2023 Q3 | 6.44 Million USD | 2560.11% |
| 2022 Q2 | 709.02 Thousand USD | 511.08% |
| 2022 Q4 | 450.27 Thousand USD | -65.53% |
| 2022 FY | 450.27 Thousand USD | 124.03% |
| 2022 Q1 | -172.47 Thousand USD | 90.8% |
| 2022 Q3 | 1.3 Million USD | 84.25% |
| 2021 Q2 | -3.95 Million USD | 14.24% |
| 2021 FY | -1.87 Million USD | 64.59% |
| 2021 Q1 | -4.61 Million USD | 12.83% |
| 2021 Q4 | -1.87 Million USD | 42.63% |
| 2021 Q3 | -3.26 Million USD | 17.44% |
| 2020 Q2 | -3.19 Million USD | 52.48% |
| 2020 FY | -5.29 Million USD | -182.41% |
| 2020 Q1 | -6.72 Million USD | -258.85% |
| 2020 Q3 | -6.09 Million USD | -90.84% |
| 2020 Q4 | -5.29 Million USD | 13.22% |
| 2019 Q3 | -1.94 Million USD | -308.25% |
| 2019 FY | -1.87 Million USD | -7247.12% |
| 2019 Q1 | 958.15 Thousand USD | 3856.72% |
| 2019 Q2 | 933.68 Thousand USD | -2.55% |
| 2019 Q4 | -1.87 Million USD | 3.63% |
| 2018 Q1 | 415.93 Thousand USD | -13.79% |
| 2018 FY | -25.5 Thousand USD | -105.29% |
| 2018 Q3 | -271.26 Thousand USD | -238.3% |
| 2018 Q2 | 196.14 Thousand USD | -52.84% |
| 2018 Q4 | -25.5 Thousand USD | 90.6% |
| 2017 FY | 482.45 Thousand USD | -37.07% |
| 2017 Q2 | 637.91 Thousand USD | 183.7% |
| 2017 Q3 | 533.34 Thousand USD | -16.39% |
| 2017 Q1 | 224.85 Thousand USD | -70.67% |
| 2017 Q4 | 482.45 Thousand USD | -9.54% |
| 2016 Q2 | 1 Million USD | 52.13% |
| 2016 FY | 766.67 Thousand USD | 209.69% |
| 2016 Q4 | 766.67 Thousand USD | -49.88% |
| 2016 Q3 | 1.52 Million USD | 52.72% |
| 2016 Q1 | 658.42 Thousand USD | 165.97% |
| 2015 Q3 | 36.65 Thousand USD | 140.32% |
| 2015 Q2 | -90.91 Thousand USD | 72.89% |
| 2015 Q1 | -335.29 Thousand USD | 52.48% |
| 2015 FY | 247.55 Thousand USD | 135.08% |
| 2015 Q4 | 247.55 Thousand USD | 575.32% |
| 2014 Q1 | -45.82 Thousand USD | 29.49% |
| 2014 Q3 | -270.84 Thousand USD | -3401.59% |
| 2014 Q2 | -7735.00 USD | 83.12% |
| 2014 FY | -705.6 Thousand USD | -985.81% |
| 2014 Q4 | -705.6 Thousand USD | -160.52% |
| 2013 Q4 | -64.98 Thousand USD | 0.0% |
| 2013 FY | -64.98 Thousand USD | -1823.74% |
| 2013 Q1 | 3378.00 USD | 0.0% |
| 2012 FY | -3378.00 USD | 0.0% |
| 2009 Q2 | 18.7 Thousand USD | 0.17% |
| 2009 Q1 | 18.67 Thousand USD | -99.9% |
| 2009 Q3 | 18.74 Thousand USD | 0.17% |
| 2008 Q2 | 18.56 Thousand USD | 2929.27% |
| 2008 Q3 | 19.06 Thousand USD | 2.71% |
| 2008 Q4 | 18.64 Million USD | 97712.52% |
| 2008 FY | 18.64 Million USD | 1052951.5% |
| 2008 Q1 | -656.00 USD | 62.96% |
| 2007 Q3 | -2411.00 USD | 73.64% |
| 2007 Q4 | -1771.00 USD | 26.55% |
| 2007 Q2 | -9148.00 USD | 0.0% |
| 2007 FY | -1771.00 USD | 86.56% |
| 2006 FY | -13.17 Thousand USD | 0.0% |
| 2006 Q4 | -13.17 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| CannBioRx Life Sciences Corp. | -655.73 Thousand USD | 1160.193% |
| BIMI International Medical Inc. | 3.11 Million USD | -122.913% |
| China Jo-Jo Drugstores, Inc. | 10.34 Million USD | 32.804% |
| Harrow Health, Inc. 8.625% Senior Notes due 2026 | 116.41 Million USD | 94.028% |
| Harrow Health, Inc. 11.875% Senior Notes due 2027 | 109.08 Million USD | 93.627% |
| Leafly Holdings, Inc. | 13.79 Million USD | 49.594% |
| Leafly Holdings, Inc. | 13.79 Million USD | 49.594% |
| LifeMD, Inc. | -14.21 Million USD | 148.908% |
| LifeMD, Inc. | -14.21 Million USD | 148.908% |
| PetMed Express, Inc. | -53.84 Million USD | 112.912% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.916% |